Current Value
$133.491 Year Return
Current Value
$133.491 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AMGN | 56.48% | $161.51B | -7.60% | 3.10% |
| RVTY | 56.35% | $12.07B | -6.76% | 0.28% |
| TMO | 55.39% | $162.60B | -20.63% | 0.38% |
| MTD | 54.54% | $25.69B | -8.98% | 0.00% |
| LYB | 53.65% | $20.99B | -30.63% | 8.42% |
| A | 53.43% | $35.27B | -5.08% | 0.80% |
| REGN | 53.17% | $60.43B | -48.18% | 0.16% |
| TECH | 53.07% | $8.53B | -28.75% | 0.60% |
| ZTS | 51.50% | $70.70B | -10.66% | 1.18% |
| IQV | 51.46% | $28.64B | -24.57% | 0.00% |
| BAX | 51.22% | $15.24B | -15.67% | 2.72% |
| LEA | 50.86% | $5.76B | -8.48% | 2.88% |
| VC | 50.22% | $2.95B | -0.40% | 0.00% |
| DHR | 50.08% | $147.08B | -16.55% | 0.57% |
| EXPD | 49.94% | $16.33B | -2.88% | 1.28% |
| DOW | 49.90% | $21.37B | -42.32% | 9.47% |
| GNTX | 49.79% | $5.23B | -31.81% | 2.06% |
| PFE | 49.72% | $146.57B | -10.05% | 6.62% |
| ITW | 49.69% | $76.80B | +9.13% | 2.31% |
| KHC | 49.68% | $31.33B | -17.74% | 6.12% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FTSM | 0.14% | $6.34B | 0.45% |
| SGOV | -0.18% | $50.93B | 0.09% |
| GLDM | 0.31% | $15.88B | 0.1% |
| GSST | -0.40% | $920.88M | 0.16% |
| SGOL | 0.42% | $5.21B | 0.17% |
| VTIP | 0.46% | $15.15B | 0.03% |
| TDTT | -0.50% | $2.63B | 0.18% |
| AGZD | 0.51% | $98.56M | 0.23% |
| IAU | 0.58% | $47.13B | 0.25% |
| OUNZ | 0.58% | $1.73B | 0.25% |
| BAR | 0.59% | $1.11B | 0.1749% |
| IBTI | -0.62% | $1.06B | 0.07% |
| KCCA | -0.64% | $108.37M | 0.87% |
| AAAU | 0.86% | $1.56B | 0.18% |
| GLD | 0.94% | $100.92B | 0.4% |
| IBTF | -1.21% | $1.98B | 0.07% |
| FXE | -1.22% | $588.06M | 0.4% |
| TPMN | -1.23% | $31.06M | 0.65% |
| XBIL | -1.33% | $784.60M | 0.15% |
| STOT | 1.36% | $252.82M | 0.45% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -35.81% | $184.73M | 0.85% |
| TAIL | -35.30% | $94.86M | 0.59% |
| IVOL | -25.18% | $342.69M | 1.02% |
| BTAL | -20.21% | $315.93M | 1.43% |
| XONE | -16.06% | $628.85M | 0.03% |
| BIL | -15.55% | $41.93B | 0.1356% |
| CLIP | -14.86% | $1.55B | 0.07% |
| FTSD | -14.37% | $233.11M | 0.25% |
| XHLF | -11.92% | $1.73B | 0.03% |
| ULST | -10.86% | $592.38M | 0.2% |
| BILS | -10.81% | $3.80B | 0.1356% |
| BILZ | -10.28% | $851.85M | 0.14% |
| TFLO | -9.47% | $6.74B | 0.15% |
| SPTS | -8.40% | $5.77B | 0.03% |
| TBLL | -8.10% | $2.12B | 0.08% |
| UTWO | -7.10% | $376.33M | 0.15% |
| BOXX | -6.82% | $6.93B | 0.19% |
| SHYM | -6.78% | $355.86M | 0.35% |
| SCHO | -6.78% | $10.98B | 0.03% |
| GBIL | -6.62% | $6.36B | 0.12% |
Yahoo
Biogen Inc. (NASDAQ:BIIB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on July 7, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen Inc. (NASDAQ:BIIB) with a price target of $208.00. The company reported a 6% year-over-year growth in total revenue to $2.4 billion, while […]
Yahoo
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK)
Yahoo
BEDFORD, Mass., & CAMBRIDGE, Mass., July 10, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a bro
Yahoo
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Barclays upgraded the company’s stock to “Overweight” from “Equal Weight” with a price objective of $57, an increase from the prior target of $51, ahead of the Tryngolza Phase 3 CORE/CORE2 data in severe hypertriglyceridemia, as reported by The […]
Finnhub
The U.S. Food and Drug Administrationapproved changing the prescribing information for Eli Lilly'sAlzheimer's drug Kisunla to allow more gradual dosing tolower the risk of a potentially dangerous...
Yahoo
Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.
Double maintains 8 strategies that include BIIB - Biogen, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HUSA | -13.98% | $20.99M | -8.33% | 0.00% |
| DFDV | -10.71% | $363.21M | +2,422.23% | 0.00% |
| TLN | -8.74% | $12.18B | +104.46% | 0.00% |
| OR | -8.12% | $5.02B | +60.19% | 0.71% |
| SFM | -6.44% | $15.53B | +91.92% | 0.00% |
| KGC | -6.10% | $18.82B | +67.10% | 0.78% |
| K | -5.89% | $27.64B | +40.17% | 2.86% |
| NGVC | -5.30% | $896.90M | +65.59% | 1.17% |
| UUU | -4.71% | $8.22M | +134.65% | 0.00% |
| TDUP | -4.53% | $807.63M | +285.88% | 0.00% |
| LITB | -4.51% | $24.26M | -71.62% | 0.00% |
| IAG | -4.21% | $4.00B | +64.30% | 0.00% |
| VSTA | -4.15% | $325.62M | +30.97% | 0.00% |
| AIFU | -4.07% | $17.40M | +87.81% | 0.00% |
| LRN | -4.02% | $5.92B | +101.30% | 0.00% |
| VHC | -3.93% | $69.05M | +176.10% | 0.00% |
| BTCT | -3.79% | $28.19M | +79.43% | 0.00% |
| VSA | -3.50% | $8.59M | -17.17% | 0.00% |
| AGX | -3.11% | $2.84B | +188.53% | 0.69% |
| AEM | -3.09% | $59.73B | +58.34% | 1.35% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BBH | 66.74% | $339.54M | 0.35% |
| RSPH | 66.08% | $721.17M | 0.4% |
| IBB | 64.34% | $5.37B | 0.45% |
| FXH | 61.99% | $891.22M | 0.62% |
| FHLC | 61.99% | $2.43B | 0.084% |
| IXJ | 61.95% | $3.75B | 0.41% |
| VHT | 61.41% | $15.34B | 0.09% |
| IYH | 61.31% | $2.72B | 0.39% |
| FBT | 61.10% | $1.02B | 0.54% |
| PPH | 60.92% | $584.35M | 0.36% |
| IHE | 60.59% | $551.02M | 0.39% |
| XLV | 60.33% | $34.17B | 0.09% |
| PBE | 59.93% | $226.91M | 0.58% |
| NOBL | 59.46% | $11.49B | 0.35% |
| KNG | 58.66% | $3.82B | 0.75% |
| XPH | 58.41% | $150.58M | 0.35% |
| MOAT | 58.11% | $12.88B | 0.47% |
| SDY | 57.81% | $20.31B | 0.35% |
| SCHD | 57.22% | $71.19B | 0.06% |
| FVD | 55.64% | $9.06B | 0.61% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CME | 0.01% | $99.17B | +44.04% | 1.75% |
| FSM | 0.02% | $2.04B | +23.33% | 0.00% |
| SCKT | 0.10% | $9.82M | +10.68% | 0.00% |
| HNRG | -0.12% | $680.74M | +95.07% | 0.00% |
| GEV | 0.17% | $147.21B | +205.24% | 0.05% |
| COUR | -0.23% | $1.35B | +14.70% | 0.00% |
| DRD | -0.25% | $1.15B | +38.33% | 2.06% |
| MVO | -0.27% | $69.00M | -38.46% | 20.74% |
| SMR | 0.30% | $4.80B | +175.80% | 0.00% |
| LQDT | -0.30% | $761.79M | +20.49% | 0.00% |
| AXON | 0.31% | $57.06B | +151.75% | 0.00% |
| SAND | -0.41% | $2.88B | +70.54% | 0.58% |
| MKTX | 0.45% | $8.21B | +2.36% | 1.37% |
| OKLO | 0.49% | $8.11B | +638.35% | 0.00% |
| BE | 0.51% | $6.00B | +93.34% | 0.00% |
| GALT | 0.53% | $155.06M | +3.81% | 0.00% |
| GRND | 0.55% | $4.18B | +74.30% | 0.00% |
| RLX | 0.64% | $2.06B | +24.86% | 0.44% |
| HMY | 0.73% | $8.95B | +43.66% | 1.20% |
| CARV | 0.73% | $9.39M | +24.99% | 0.00% |
